Back to search
FDAFDA · Food and drugs·Recall number D-1347-2022

PF-Labetalol HCl Injection, USP, 20 mg/4 mL (5 mg/mL), One 4 mL Unit-Dose Vial, packaged in 30 x 4 mL Sterile Unit-dose Vials per carton, Rx Only, Nephron 503B Outsourcing Facility, 4500 12th Street Extension, West Columbia, SC 29172; NDC 69374-946-34

Published August 24, 2022 · Recall initiated: August 10, 2022

Summary

FDA records drug Class II recall D-1347-2022, published August 24, 2022 and initiated August 10, 2022. Recalling firm: Nephron Sterile Compounding Center LLC; Status: Terminated; Reported quantity: 33,870 vials; Lot: Lot: LB2005A, Exp 3/2/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Potential for cross-contamination due to product carryover during manufacturing.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Nephron Sterile Compounding Center LLC
Distributor
Nationwide in the USA
Lot
Lot: LB2005A, Exp 3/2/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was PF-Labetalol HCl Injection, USP, 20 mg/4 mL (5 mg/mL), One 4 mL Unit-Dose Vial, packaged in 30 x 4 mL Sterile Unit-dose Vials per carton, Rx Only, Nephron 503B Outsourcing Facility, 4500 12th Street Extension, West Columbia, SC 29172; NDC 69374-946-34 recalled?

Yes. FDA published recall D-1347-2022 on August 24, 2022. Reported hazard: CGMP Deviations: Potential for cross-contamination due to product carryover during manufacturing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter